Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS JANUARY ISSUE PUBLISHED
  • JANUARY 2021 Issue has been successfully launched on 1 January 2021.

Abstract

CLINICAL OUTCOMES AND TOLERABILITY OF SACUBITRIL-VALSARTAN COMBINATION IN PATIENTS WITH HEART FAILURE

Nayini Sayika*, K. Vinod, T. Vamshi Krishna, Dr. Sushmitha, Dr. A. V. Kishore Babu and Dr. A. Srinivasa Rao

ABSTRACT

Background: Heart failure sometimes called as Congestive heart failure, occurs when heart muscles doesn't pump as well as it should. Certain conditions such as narrowed arteries in your heart (Coronary heart disease) o high blood pressure, gradually leave your heart too weak or too stiff to fill and pump efficiently. Methodology: A total of 101 patients were considered. Informed consent was obtained from all the subject care takers. Subjects enrolled in the study were admitted in ICU's and OP department. The study appraises the clinical outcomes of sacubitril-valsartan by detecting NYHA and LV Ejection fraction and evaluated the tolerability of the sacubitril-valsartan by detecting adverse effects of the drug. Results: Out of 101 patients 74 patients (74.3%) were found to be males and 27 patients (26.7%) were found to be females. Most of the patients were of elderly people. Most of the patients were diagnosed as suffering from CAD. Conclusion: Out of 101 patients treated with sacubitril – valsartan combination, most of the patients were tolerable to this drug. The outcomes such as elevated serum creatinine and serum electrolytes were almost normal.

Keywords: Sacubitril, valsartan, NYHA, LVEF, LCZ696, ARNI.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More